Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13


A phase I study of indoximod in patients with advanced malignancies.

Soliman HH, Minton SE, Han HS, Ismail-Khan R, Neuger A, Khambati F, Noyes D, Lush R, Chiappori AA, Roberts JD, Link C, Vahanian NN, Mautino M, Streicher H, Sullivan DM, Antonia SJ.

Oncotarget. 2016 Apr 19;7(16):22928-38. doi: 10.18632/oncotarget.8216.


A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors.

Amin M, Minton SE, LoRusso PM, Krishnamurthi SS, Pickett CA, Lunceford J, Hille D, Mauro D, Stein MN, Wang-Gillam A, Trull L, Lockhart AC.

Invest New Drugs. 2016 Feb;34(1):84-95. doi: 10.1007/s10637-015-0306-7. Epub 2015 Dec 1.


The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.

DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ.

Clin Cancer Res. 2015 Jul 1;21(13):2911-5. doi: 10.1158/1078-0432.CCR-14-1760. Epub 2015 Feb 24.


Evolutionary approaches to prolong progression-free survival in breast cancer.

Silva AS, Kam Y, Khin ZP, Minton SE, Gillies RJ, Gatenby RA.

Cancer Res. 2012 Dec 15;72(24):6362-70. doi: 10.1158/0008-5472.CAN-12-2235. Epub 2012 Oct 12.


Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.

Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, Xu P, Carter WB, Minton SE.

J Clin Oncol. 2012 Feb 10;30(5):533-8. doi: 10.1200/JCO.2011.34.6890. Epub 2012 Jan 9.


Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial.

Robert NJ, Saleh MN, Paul D, Generali D, Gressot L, Copur MS, Brufsky AM, Minton SE, Giguere JK, Smith JW 2nd, Richards PD, Gernhardt D, Huang X, Liau KF, Kern KA, Davis J.

Clin Breast Cancer. 2011 Apr;11(2):82-92. doi: 10.1016/j.clbc.2011.03.005. Epub 2011 Apr 11. Erratum in: Clin Breast Cancer. 2011 Aug;11(4):273.


A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.

Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE.

Br J Cancer. 2011 Jun 7;104(12):1828-35. doi: 10.1038/bjc.2011.156. Epub 2011 May 10.


First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.

Munster PN, Britten CD, Mita M, Gelmon K, Minton SE, Moulder S, Slamon DJ, Guo F, Letrent SP, Denis L, Tolcher AW.

Clin Cancer Res. 2007 Feb 15;13(4):1238-45.


Chemotherapy-induced amenorrhea and fertility in women undergoing adjuvant treatment for breast cancer.

Minton SE, Munster PN.

Cancer Control. 2002 Nov-Dec;9(6):466-72. Review.


New Hormonal Therapies for Breast Cancer.

Minton SE.

Cancer Control. 1999 May;6(3):247-255.


Breast Cancer Treatment: Prospects for the Future.

Minton SE.

Cancer Control. 1999 May;6(3):215-217. No abstract available.


Chemoprevention of breast cancer in the older patient.

Minton SE.

Hematol Oncol Clin North Am. 2000 Feb;14(1):113-30. Review.


Severe Lhermitte-Duclos disease with unique germline mutation of PTEN.

Sutphen R, Diamond TM, Minton SE, Peacocke M, Tsou HC, Root AW.

Am J Med Genet. 1999 Feb 12;82(4):290-3.


Supplemental Content

Loading ...
Support Center